Vurdering af reguleringsmæssige behov - liste
Vurdering af reguleringsmæssige behov - liste
The assessment of regulatory needs list includes substances for which an assessment either is under development or has been completed.
For each substance, the table shows the assessing authority (submitter), the concern, the status and the suggested follow-up action, and the date of the latest update to the list entry.
Other process details and relevant documents are also available and can be accessed through the ‘Details’ icon for the list entry.
Regulatory Management Option Analysis (RMOA) are assessments of regulatory needs. Publication of RMOA was initiated in February 2013 with the start of the implementation of the SVHC Roadmap. In 2019, authorities and in particular ECHA have moved to address more groups of substances.
The responsibility for the content of an assessment of regulatory needs rests with the authority that developed it. It is possible that other authorities do not have the same view and may develop a further assessment of regulatory needs for the same (group of) substances. Assessment of regulatory needs and their conclusions are compiled based on available information and may change in light of new information or further assessment.
Last updated 25 april 2024. Database contains 5009 unique substances/entries.
|
201-064-4
|
77-86-1
|
ECHA
|
Under development
|
No action
|
16-sep.-2022
|
Details | ||
|
201-058-1
|
77-78-1
|
ECHA
|
Under development
|
No action
|
23-apr.-2020
|
Details | ||
|
201-052-9
|
77-73-6
|
ECHA
|
Under development
|
Pending action
|
11-dec.-2023
|
Details | ||
|
201-025-1
|
77-40-7
|
France
|
Endocrine disruption |
Under development
|
No suggestion yet
|
Details | ||
|
201-025-1
|
77-40-7
|
ECHA
|
Under development
|
Other action
|
16-dec.-2021
|
Details | ||
|
201-016-2
|
77-25-8
|
ECHA
|
Under development
|
No action
|
25-jan.-2021
|
Details | ||
|
231-718-4
|
7699-45-8
|
ECHA
|
Under development
|
CLH
|
17-aug.-2023
|
Details | ||
|
231-717-9
|
7699-43-6
|
ECHA
|
Under development
|
No action
|
03-mar.-2022
|
Details | ||
|
231-716-3
|
7699-41-4
|
ECHA
|
CLH
|
17-okt.-2022
|
Details | |||
|
231-714-2
|
7697-37-2
|
Germany
|
Other human toxicity |
Concluded
|
CLH
|
23-sep.-2014
|
Details | |
|
212-215-9
|
769-92-6
|
ECHA
|
Under development
|
No action
|
19-apr.-2023
|
Details | ||
|
212-214-3
|
769-78-8
|
ECHA
|
Concluded
|
CLH
|
28-jan.-2020
|
Details | ||
|
212-200-7
|
768-90-1
|
ECHA
|
Under development
|
Pending action
|
04-okt.-2021
|
Details | ||
|
212-199-3
|
768-66-1
|
ECHA
|
Under development
|
No action
|
13-dec.-2023
|
Details | ||
|
4-PHENYL-1-BUTENE; SQ 31,175; SQ31175
|
405-980-7
|
768-56-9
|
ECHA
|
Under development
|
No action
|
25-sep.-2023
|
Details | |
|
626-527-1
|
768-56-9
|
ECHA
|
Under development
|
No action
|
25-sep.-2023
|
Details | ||
|
212-193-0
|
768-33-2
|
ECHA
|
Under development
|
No action
|
18-dec.-2023
|
Details | ||
|
231-640-0
|
7665-72-7
|
ECHA
|
Under development
|
CLH
|
01-jul.-2021
|
Details | ||
|
616-366-5
|
76649-15-5
|
ECHA
|
Under development
|
CLH Restriction |
26-jul.-2022
|
Details | ||
|
231-639-5
|
7664-93-9
|
Belgium
|
Carcinogenic Exposure Mutagenic |
Under development
|
No suggestion yet
|
Details | ||
|
278-503-1
|
76622-74-7
|
ECHA
|
Under development
|
No action
|
11-mar.-2022
|
Details | ||
|
212-161-6
|
766-09-6
|
ECHA
|
Under development
|
CCH
|
13-dec.-2023
|
Details | ||
|
212-157-4
|
766-05-2
|
ECHA
|
Under development
|
No action
|
03-dec.-2021
|
Details | ||
|
816-311-7
|
76589-16-7
|
ECHA
|
Under development
|
No action
|
22-apr.-2021
|
Details | ||
|
BRIGHTENER SM 1018 CONC.; LEUCOPHOR BCR
|
405-280-1
|
76508-02-6
|
ECHA
|
Under development
|
Pending action
|
05-sep.-2022
|
Details | |
|
212-153-2
|
765-69-5
|
ECHA
|
Under development
|
No action
|
27-jun.-2022
|
Details | ||
|
212-146-4
|
765-43-5
|
ECHA
|
Under development
|
No action
|
22-dec.-2023
|
Details | ||
|
402-600-1
|
765-12-8
|
ECHA
|
Under development
|
No action
|
30-nov.-2020
|
Details | ||
|
231-600-2
|
7647-17-8
|
ECHA
|
Under development
|
Pending action
|
11-maj-2022
|
Details | ||
|
231-599-9
|
7647-15-6
|
ECHA
|
Under development
|
CLH
|
21-jan.-2022
|
Details | ||
|
231-592-0
|
7646-85-7
|
ECHA
|
Under development
|
No action
|
17-aug.-2023
|
Details | ||
|
231-589-4
|
7646-79-9
|
ECHA
|
Carcinogenic Mutagenic Toxic for reproduction |
Concluded
|
Restriction
|
09-jun.-2017
|
Details | |
|
231-588-9
|
7646-78-8
|
ECHA
|
Under development
|
CCH
|
27-okt.-2023
|
Details | ||
|
212-133-3
|
764-99-8
|
ECHA
|
Under development
|
No action
|
30-nov.-2020
|
Details | ||
|
810-394-3
|
76326-99-3
|
ECHA
|
Under development
|
No action
|
16-sep.-2022
|
Details | ||
|
231-561-1
|
7632-51-1
|
ECHA
|
Under development
|
CLH Other action |
19-maj-2021
|
Details | ||
|
231-559-0
|
7632-10-2
|
ECHA
|
Under development
|
No action
|
11-jan.-2022
|
Details | ||
|
231-551-7
|
7631-95-0
|
ECHA
|
Under development
|
No action
|
11-maj-2022
|
Details | ||
|
231-545-4
|
7631-86-9
|
ECHA
|
CLH
|
17-okt.-2022
|
Details | |||
|
482-010-9
|
762300-77-6
|
ECHA
|
Under development
|
No action
|
21-apr.-2023
|
Details | ||
|
231-540-7
|
7623-09-8
|
ECHA
|
Under development
|
No action
|
01-jul.-2022
|
Details | ||
|
212-094-2
|
762-16-3
|
ECHA
|
Concluded
|
No action
|
12-jun.-2020
|
Details | ||
|
212-092-1
|
762-12-9
|
ECHA
|
Concluded
|
No action
|
12-jun.-2020
|
Details | ||
|
212-091-6
|
762-04-9
|
ECHA
|
Under development
|
Pending action
|
17-dec.-2021
|
Details | ||
|
616-298-6
|
76169-00-1
|
ECHA
|
Concluded
|
No action
|
15-nov.-2021
|
Details | ||
|
212-090-0
|
761-65-9
|
ECHA
|
Under development
|
CCH
|
17-maj-2021
|
Details | ||
|
231-512-4
|
7601-90-3
|
Germany
|
Endocrine disruption |
Under development
|
No suggestion yet
|
Details | ||
|
212-084-8
|
760-93-0
|
ECHA
|
Under development
|
Other action
|
08-jul.-2021
|
Details | ||
|
200-986-4
|
76-83-5
|
ECHA
|
Under development
|
No action
|
17-feb.-2022
|
Details | ||
|
200-981-7
|
76-72-2
|
ECHA
|
Under development
|
No action
|
25-jan.-2021
|
Details | ||